Charite Research Organisation GmbH — Clinical Trial Site

65 Registered trials

18 Currently recruiting

Organisation

Charite Research Organisation GmbH

Location

Berlin, Germany

Identifier

ORG-100028160

Address

Hamato Onkologische Phase-I Unit, Hindenburgdamm 30, Lichterfelde, 12203, Germany

Departments

#2000: Pruefzentrum
#4902:Dermatology, Venerology and Allergology
#6001; Pruefzentrum
1001
1003
3008:CRO
Charité - Universitätsmedizin Berlin
Charite Research Organisation
Charité Research Organisation GmbH
Charité Universitätsmedizin Berlin
CRO
Department of Dermatology, Venerology and Allergology
Department of Infectious Diseases and Respiratory Medicine, Charité Berlin
Division of Oncology and Hematology
Gynecology
Hamato Onkologische Phase-I Unit
Hemato-oncology
Hematology, Oncology and tumor immunology
Kinik und Hochschulambulanz für Neurologie
Klinik für Dermatologie, Venerologie u. Allergologie
Klinik und Hochschulambulanz für Neurologie
Medical Operations
Medizinische Klinik m.S. Nephrologie
Medizinische Klinik mit Schwerpunkt Haematologie, Onkologie und Tumorimmunologie (CBF)
Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
Medizinische Klinik, Haematologie/Onkologie, Tumorimmunologie
N/A
NA
Nephrology and Medical Intensive Care
Neurologie, Neurochirurgie und Psychiatrie
Not applicable
Oncology
Psychiatry and Psychotherapy
Rheumatology and Clinical Immunology
Uro-Onkologisches Studiendepartment

Clinical trials at this site (65)

Search interface

A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k… Not authorised

2022-501389-23-00 end-stage renal disease or otherwise an insufficient ki 4
A two part, randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and … Not authorised

2022-503145-22-00 Pseudomonas colonization 1
A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k… Pending

2022-501389-23-02 end-stage renal disease or otherwise an insufficient ki 4
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate… Pending

2025-520978-18-00 Chronic Kidney Disease 1
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzyme… Pending

2025-524060-38-00 Active Ulcerative Colitis (UC) 3
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 LA/mGC/GEJC (locally advanced unresectable or metastati 9 2024-08-16
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum… Recruiting

2023-509335-60-00 Advanced solid tumors including (but not limited to), n 1 2023-02-23
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/p… Recruiting

2025-524328-24-00 Ulcerative colitis 3 2026-05-06
A Trial of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE) Recruiting

2025-521742-15-00 Treatment of Late Isolated Microvascular Inflammation i 4 2026-03-03
A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G… Recruiting

2023-508612-29-00 Advanced Melanoma 5 2025-11-07
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy … Recruiting

2024-511178-66-00 Myotonic Dystrophy type 1 and type 2 (DM1/DM2) 5 2025-09-12
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Prelimina… Recruiting

2025-522126-13-00 Cold Induced Urticaria 1 2025-08-29
A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder. Recruiting

2024-514296-17-00 Attention deficit hyperactivity disorder 3 2025-08-05
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safe… Recruiting

2024-517644-62-00 Mild to Moderate Asthma 1 2025-06-30
A study to test how well different doses of BI 3031185 are tolerated by healthy men and women Recruiting

2024-516921-29-00 Healthy volunteer trial 3 2025-03-25
A Study to Test the Activity and Safety of Vixarelimab in Patients with Moderate to Severe Active Ulcerative Colitis Recruiting

2024-516287-29-00 Moderate to Severe Active Ulcerative Colitis (UC) 3 2025-02-26
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During… Recruiting

2024-511179-13-00 Myotonic Dystrophy type 1 and type 2 (DM1/DM2) 5 2025-01-13
A study in healthy men to test how well different doses of BI 3776528 are tolerated Recruiting

2024-515222-92-00 Healthy volunteer trial 1 2025-01-08
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Colon cancer 5 2024-10-22
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in C… Recruiting

2023-507611-35-00 mild to moderate asthma 1 2024-03-01
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with u… Recruiting

2023-507547-11-00 Ulcerative colitis 1 2024-02-09
Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa)… Recruiting

2024-511794-30-00 Multiple Myeloma 9 2023-06-28
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o… Recruiting

2024-514328-18-00 Spinocerebellar ataxia types 1, 3 and Huntington's dise 7 2022-12-06
A study to investigate the safety and tolerability of SDL-M1 nanoparticles in healthy volunteers Ended

2024-518889-27-00 Septic cholestasis 1 2026-04-02